Our Company
page-template,page-template-full_width,page-template-full_width-php,page,page-id-446,qode-social-login-1.1.3,qode-restaurant-1.1.1,stockholm-core-1.1,select-theme-ver-5.1.8,ajax_fade,page_not_loaded,smooth_scroll,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

Our Company

About Metaclipse Therapeutics

Metaclipse Therapeutics Corporation aims to be a leader in developing next-generation immunotherapies to treat cancer & vaccines to prevent infectious diseases using our proprietary biological adjuvants. Our personalized immunotherapy platform, Membrex™, has demonstrated promising preclinical data across multiple solid tumors with Phase 1 clinical trials for triple negative breast cancer (TNBC) and head and neck cancer (HNSCC) to begin in early 2024. We are committed to continuous innovation using biological adjuvants for therapeutic and preventative vaccines.

Our Team

Periasamy Selvaraj, Ph.D.

Chief Scientific Officer


Michael Coleman, Ph.D.

Senior Vice President, Strategy


Kamal Kannan, Ph.D.

Vice-President, Product Development

Christopher Pack, Ph.D.

Director, Preclinical Studies

Sampath Ramachandiran, Ph.D.

Director, Product Development

Kristen Jacobsen, Ph.D.

Senior Scientist

Rajesh Gupta, Ph.D.

Scientific Advisor

Rafi Ahmed, Ph.D.

Scientific Advisor

William C. Wood, M.D.

Scientific Advisor

Peter E Jensen MD

Peter Jensen, M.D.

Scientific Advisor

Research Partners & Collaborators

Membrex™ and VaxRex™ are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.

 Harnessing the Immune System to Seek Out and Destroy Cancer

If you are interested in getting involved with or learning more about our drug development efforts, please contact us.